Among patients with advanced melanoma, those who received both nivolumab (Opdivo) and ipilimumab (Yervoy) had improved overall survival compared with those who received only ipilimumab and appeared to have more favourable survival outcomes compared with...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nSkFJn
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Cutaneous squamous cell carcinoma (cSCC) are amongst the most common cancers with metastatic potential. Specific clinical and pathological “...
-
PSA! Has a TON of Scholarship Opportunities Right Now. SPOILER: college is crazy-expensive. Sorry. Did we spoil it? There are... from #Ale...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1tk1BEi via IFTTT
-
Fun math practice! Improve your skills with free problems in 'Solve two-step equations' and thousands of other practice lessons. f...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2p6KhjG via IFTTT
-
Purpose. To assess the long-term clinical outcomes of conventional laser in situ keratomileusis (LASIK) for moderate to high myopia. Methods...
-
<div style=font-size:12px;text-align:center;>Vote for on globolister:<br /><a href=http:///details?site=2916&vote=1 targe...
-
How to Write a Master's Thesis. Students learning how to write a Master's Thesis will first learn that a central thesis question mus...
-
Abstract Shiga toxin-producing Escherichia coli (STEC) may cause haemolytic uraemic syndrome (HUS). Age ≤5 years and presence of stx2a a...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου